TY - JOUR
T1 - Comparable efficacy of low- versus high-dose induction corticosteroid treatment in autoimmune pancreatitis
AU - Buijs, Jorie
AU - Van Heerde, Marianne J.
AU - Rauws, Erik A.J.
AU - De Buy Wenniger, Lucas J.Maillette
AU - Hansen, Bettina E.
AU - Biermann, Katharina
AU - Verheij, Joanne
AU - Vleggaar, Frank P.
AU - Brink, Menno A.
AU - Beuers, Ulrich H.W.
AU - Kuipers, Ernst J.
AU - Bruno, Marco J.
AU - Van Buuren, Henk R.
PY - 2014/3
Y1 - 2014/3
N2 - OBJECTIVE: The objective of this study was to compare efficacy of high versus low doses of prednisone for induction of remission in autoimmune pancreatitis (AIP). METHODS: This is a retrospective, multicenter study including patients diagnosed with AIP between May 1992 and August 2011. Clinical, laboratory and imaging findings were assessed before treatment and at 1, 3, and 6 months after starting treatment. RESULTS: A total of 65 patients (57 males; median age, 63 years) were treated with an initial low dose (10-20 mg/d, n = 14), a medium dose (30 mg/d, n = 15), or a high dose (40-60 mg/d, n = 36) of prednisone. There were no significant differences in baseline characteristics between the treatment groups including age, presenting symptoms and laboratory results. During a follow-up period of 6 months, in nearly all patients, symptoms (jaundice, weight loss) resolved completely. After 6 months, treatment response with respect to symptomatic, radiological, and laboratory improvement was comparable for the different dosage groups. CONCLUSIONS: Response to therapy was comparable for AIP patients treated with doses of prednisone in the range of 10 to 60 mg/d. A prospective trial should be conducted to confirm efficacy of lower-dose prednisone treatment.
AB - OBJECTIVE: The objective of this study was to compare efficacy of high versus low doses of prednisone for induction of remission in autoimmune pancreatitis (AIP). METHODS: This is a retrospective, multicenter study including patients diagnosed with AIP between May 1992 and August 2011. Clinical, laboratory and imaging findings were assessed before treatment and at 1, 3, and 6 months after starting treatment. RESULTS: A total of 65 patients (57 males; median age, 63 years) were treated with an initial low dose (10-20 mg/d, n = 14), a medium dose (30 mg/d, n = 15), or a high dose (40-60 mg/d, n = 36) of prednisone. There were no significant differences in baseline characteristics between the treatment groups including age, presenting symptoms and laboratory results. During a follow-up period of 6 months, in nearly all patients, symptoms (jaundice, weight loss) resolved completely. After 6 months, treatment response with respect to symptomatic, radiological, and laboratory improvement was comparable for the different dosage groups. CONCLUSIONS: Response to therapy was comparable for AIP patients treated with doses of prednisone in the range of 10 to 60 mg/d. A prospective trial should be conducted to confirm efficacy of lower-dose prednisone treatment.
KW - IgG4
KW - autoimmune pancreatitis
KW - steroid therapy
UR - http://www.scopus.com/inward/record.url?scp=84894452095&partnerID=8YFLogxK
U2 - https://doi.org/10.1097/MPA.0000000000000044
DO - https://doi.org/10.1097/MPA.0000000000000044
M3 - Article
C2 - 24518506
SN - 0885-3177
VL - 43
SP - 261
EP - 267
JO - Pancreas
JF - Pancreas
IS - 2
ER -